ondansetron has been researched along with clozapine in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 9 (37.50) | 29.6817 |
| 2010's | 8 (33.33) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bojarski, AJ; Dehaen, W; Janousek, J; Juza, R; Karasova, JZ; Kobrlova, T; Korabecny, J; Kubacka, M; Mezeiova, E; Mogilski, S; Musilek, K; Pejchal, J; Petrasek, T; Prchal, L; Randakova, A; Satala, G; Soukup, O; Stark, H; Stefkova-Mazochova, K; Svozil, D; Vlcek, P; Vojtechova, I | 1 |
| Brown, D; Factor, SA; Molho, ES; Podskalny, GD | 1 |
| Mol, CA; Schinkel, AH; van Deemter, L; Wagenaar, E | 1 |
| Brawman-Mintzer, O; Mintzer, JE | 1 |
| Baylé, FJ; Olié, JP | 1 |
| Briskin, JK; Curtis, JL | 1 |
| Saederup, E; Squires, RF | 1 |
| Eap, CB; Voirol, P; Zullino, DF | 1 |
| Bauzon, D; Bymaster, FP; Cohen, ML; DeLapp, NW; Falcone, JF; Kennedy, JS; Schenck, K | 1 |
| Hema, T; Maran, S; Subhashini, G | 1 |
4 review(s) available for ondansetron and clozapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Parkinson's disease: drug-induced psychiatric states.
Topics: Aged; Anxiety; Bipolar Disorder; Clozapine; Depression; Electroconvulsive Therapy; Humans; Levodopa; Lisuride; Male; Ondansetron; Parkinson Disease; Psychoses, Substance-Induced; Sexual Dysfunctions, Psychological | 1995 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepine; Clozapine; Combined Modality Therapy; Decision Trees; Dementia; Humans; Ondansetron; Psychomotor Agitation; Serotonin; Trazodone | 1996 |
[New drug therapies].
Topics: Brain; Clozapine; Humans; Ondansetron; Psychiatric Status Rating Scales; Psychotropic Drugs; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 1996 |
20 other study(ies) available for ondansetron and clozapine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Novel D
Topics: Animals; Antipsychotic Agents; Piperazines; Rats; Rats, Wistar; Receptors, Serotonin; Schizophrenia | 2022 |
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Clozapine; Diffusion; Domperidone; Epithelium; Flunitrazepam; Haloperidol; Humans; Kidney; Kinetics; Loperamide; Male; Mice; Mice, Inbred Strains; Ondansetron; Phenytoin; Recombinant Proteins; Structure-Activity Relationship; Swine; Tissue Distribution; Transfection | 1996 |
Augmentation of clozapine therapy with ondansetron.
Topics: Adult; Animals; Chronic Disease; Clozapine; Drug Synergism; Drug Therapy, Combination; Humans; Male; Ondansetron; Psychiatric Status Rating Scales; Rabbits; Schizophrenia; Severity of Illness Index | 1997 |
Clozapine's antipsychotic effects do not depend on blockade of 5-HT3 receptors.
Topics: Animals; Antipsychotic Agents; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Clozapine; Drug Interactions; Female; GABA Antagonists; gamma-Aminobutyric Acid; Male; Ondansetron; Quinacrine; Quipazine; Rats; Rats, Sprague-Dawley; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Sulfur Radioisotopes; Tropanes | 1999 |
Ondansetron for tardive dyskinesia.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Olanzapine; Ondansetron; Pirenzepine; Receptors, Serotonin; Serotonin Antagonists | 2001 |
Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.
Topics: Animals; Benzodiazepines; Binding, Competitive; Clozapine; Dibenzothiazepines; Dose-Response Relationship, Drug; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Haloperidol; HeLa Cells; Humans; Ileum; In Vitro Techniques; Indoles; Lysergic Acid; Muscle Contraction; Olanzapine; Ondansetron; Pirenzepine; Quetiapine Fumarate; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfur Radioisotopes; Tritium; Tropisetron | 2001 |
Adjunctive ondansetron in schizophrenia--A pilot study.
Topics: Adult; Amisulpride; Antipsychotic Agents; Clozapine; Drug Therapy, Combination; Feasibility Studies; Humans; Ondansetron; Pilot Projects; Schizophrenia; Sulpiride; Treatment Outcome | 2016 |